logo
  Join        Login             Stock Quote

Pfizer (PFE): Lyrica Nerve-Pain Treatment Fails In Diabetes Study, Stops HIV Trial

 May 04, 2012 10:11 AM
 


(By Balachander) Pfizer Inc. (NYSE:PFE) said a late-stage trial of its Lyrica nerve-pain treatment failed to meet main objective of a specified change in pain and said it stopped a similar study involving patients with HIV neuropathy.

The company's phase 3 trial tested Lyrica in patients suffering with diabetes-related nerve damage.

Meanwhile, an interim analysis of a similar study in patients with neuropathic pain associated with HIV neuropathy showed that the improvements in neuropathic pain symptoms were virtually same between the Lyrica and placebo treatments.

Lyrica is not approved in the U.S. for the treatment of neuropathic pain associated with HIV neuropathy. Sales of Lyrica grew 16 percent to $955 million in the first quarter.

[Related -Pfizer Inc. (PFE) Q3 Earnings Preview: What To Watch?]

Pharmaceutical companies like Pfizer are seeking to expand use of current drugs to offset the loss of patents on key drugs.

In the United States, Lyrica capsules CV is approved to treat diabetic nerve pain, pain after shingles, fibromyalgia and partial onset seizures in adults with epilepsy who take one or more drugs for seizures.

Painful diabetic peripheral neuropathy is a form of nerve damage characterized by burning pain, pins and needles, or shooting pain in the feet and often in the hands as well. Around 20 percent of people with diabetes experience pain resulting from nerve damage, Pfizer noted.

iOnTheMarket Premium
Advertisement

Advertisement


Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

rss feed

Latest Stories

article imageThree Stocks to Consider in a Hot Sector

Healthcare stocks have performed handsomely in August, at least so far anyway. For instance, First Trust read on...

article imageOmniVision Technologies, Inc. (OVTI) Q1 Earnings Preview: Hard to See Sales Up, EPS Down

OmniVision Technologies, Inc. (NASDAQ:OVTI) will release its financial results for the first quarter of read on...

article imageAvago Technologies Ltd. (AVGO) Q3 Earnings Preview: Going For 20 in a Row

Avago Technologies Ltd. (NASDAQ:AVGO) will report its third quarter fiscal year 2014 financial results and read on...

article imageLevel 3 Communications, Inc. (LVLT): A Good Time To Buy Says Macquarie

On a day Wall Street is struggling to advance, Level 3 Communications, Inc. (NYSE:LVLT) is having no such read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.